• Protease Inhibitor Switch Study
• HIV Study for Multiply Treated People Who Are Failing Their Current Regimen
• Tipranavir Early Access Program

Protease Inhibitor Switch Study

Swedish Medical Center is looking for HIV-positive people to participate in a research study that will replace Kaletra® with a currently marked protease inhibitor to see if it will improve cholesterol levels. To take part in this study, your current viral load must be <50 copies/mL. This is a 48-week trial that includes:

• Laboratory testing

• Physical exams
  Advertisement
• Some medications

• Reimbursement for travel and childcare

For more information please call Heather at (206) 386-2820.

HIV Study for Multiply Treated People Who Are Failing Their Current Regimen

Study Drug: An investigational protease inhibitor with a combination of other drugs.

Length: 48 weeks. Study related lab tests, including genotyping and physical exams are free. The investigational drug is provided at no cost. Reimbursement for childcare and transportation are possible. Will work around your schedule (evenings, weekends, etc.)

Please contact Janice for more details at (206) 386-2523.

Tipranavir Early Access Program

A limited number of spaces in the Tipranavir early access program are available to persons with private providers and through the Madison Clinic. Patients must have a CD4 count <100 copies/mm³.

For more information please call Heather at (206) 386-2820.